These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9710942)

  • 1. Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
    Sato T; Oouchi M; Nagakubo H; Chiba T; Ogawa S; Sato C; Sugimura K; Fukuda M
    Tohoku J Exp Med; 1998 May; 185(1):25-9. PubMed ID: 9710942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients.
    Miossec P; Zkhiri F; Pariès J; David-Dufilho M; Devynck MA; Valensi PE
    Diabet Med; 1999 May; 16(5):424-30. PubMed ID: 10342343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
    Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
    Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients.
    Takahashi T; Ishii N; Itai K; Goto R; Higashi K; Kobori S
    J Atheroscler Thromb; 2005; 12(3):149-53. PubMed ID: 16020915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
    Endo K; Miyashita Y; Saiki A; Oyama T; Koide N; Ozaki H; Otsuka M; Ito Y; Shirai K
    J Atheroscler Thromb; 2004; 11(6):341-7. PubMed ID: 15644588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin sodium, a new HMG-CoA reductase inhibitor.
    Raasch RH
    DICP; 1991 Apr; 25(4):388-94. PubMed ID: 1926908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
    Watanabe T; Sugiyama H; Uchimura I; Maezawa H
    Diabetes Res Clin Pract; 1991 Nov; 14(2):107-12. PubMed ID: 1756681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
    Nishimura R; Sone H; Nakagami T; Tajima N
    Diabetes Res Clin Pract; 2013 May; 100(2):e31-3. PubMed ID: 23522341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus.
    Kim JH; Lee MR; Shin JA; Lee SS; Lee JM; You SJ; Yoon KH; Chang SA
    Atherosclerosis; 2013 Apr; 227(2):355-9. PubMed ID: 23466100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.
    Muramatsu J; Kobayashi A; Hasegawa N; Yokouchi S
    Atherosclerosis; 1997 Apr; 130(1-2):179-82. PubMed ID: 9126662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
    Ito H; Ouchi Y; Ohashi Y; Saito Y; Ishikawa T; Nakamura H; Orimo H
    J Atheroscler Thromb; 2001; 8(2):33-44. PubMed ID: 11770708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin.
    Porreca E; Di Febbo C; Baccante G; Di Nisio M; Cuccurullo F
    J Am Coll Cardiol; 2002 Jun; 39(11):1752-7. PubMed ID: 12039487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
    Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin: a new drug for the treatment of hypercholesterolemia.
    Jungnickel PW; Cantral KA; Maloley PA
    Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
    Akanji AO; Osifo E; Kirk M; Hockaday TD
    Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
    Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
    Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.